As mentioned above, the long half-lives and high levels of enzalutamide and BMS-641988 in the CNS may induce seizures in a small proportion of prostate cancer patients, as these AR antagonists can competitively bind and inhibit GABA-α activity [18, 32, 48, 54, 55]. Here, AR is linked to prostate cancer.